Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

Phase 4

Recruiting

• Conditions: Alzheimer Disease
• Interventions: Drug: Placebo; Drug: Memantine

• Registration Number: NCT03703856
• Lead Sponsor: University of California, San Diego

Brief Summary

The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-10-09
• Study First Submitted QC: 2018-10-10
• Study First Posted: 2018-10-12
• Study Start: 2019-01-31
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-04
• Last Update Posted: 2024-11-06
• Primary Completion: 2025-02-28
• Study Completion: 2025-05-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Memantine	Memantine	-

Primary Outcome Measures

Name	Time	Method
Change from baseline measure in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 8, 16 and 24 weeks	0, 8, 16, 24 weeks	measures cognitive ability

Secondary Outcome Measures

Name	Time	Method
Change from baseline measure in Neuropsychiatric Inventory-Questionnaire (NPI-Q) at 8, 16 and 24 weeks	0, 8, 16, 24 weeks	measures behavioral symptoms

Trial Locations

Locations (1)

Clinical Teaching Facility (CTF-B102) at UCSD Medical Center; 🇺🇸 San Diego, California, United States